ACCEL DIAGNOSTICS, LLC

Houston, TX · Medtech · Private

RapidQCT, a quantitative point-of-care serological blood test that measures COVID-19 antibody titers

acceldx.com →
Grants
$4.9M
13 awards
Sector median: 1
Raised
—
No Form D on record
Contracts
$937K
2 awards · Health and Human S
#328 of 4531 in medtech
Patents
—
No published records under this name
Sector median: 2

Capital Timeline

Federal above the line · equity below · node area scaled to amount
Capital and federal award history
DateEventSourceAmount
Federal grantDepartment of Health and Human Services · Phase I · A disposable assay for the monitoring of heart failure in the home setting$225,133
Federal grantDepartment of Health and Human Services · Phase I · A rapid instrument-free diagnostic assay for the early detection and quantification of sepsis biomarkers in blood$145,499
Federal grantDepartment of Health and Human Services · Phase I · I Corps Program for A rapid instrument free diagnostic assay for the early detection and quantification of sepsis biomarkers in blood$194,545
Federal contractDepartment of Health and Human Services · Igf::ot::igf SBIR Topic #97 - Phase I - Minimally Invasive Test For Chemotherapy-induced Cardiotoxicity$212,552
Federal grantDepartment of Health and Human Services · Phase I · I-Corps Program for A rapid instrument-free diagnostic assay for the early detection and quantification of sepsis biomarkers in blood.$49,046
Federal grantDepartment of Health and Human Services · Phase II · A disposable assay for the monitoring of heart failure in the home setting.$943,624
Federal grantDepartment of Health and Human Services · Phase II · A disposable assay for the monitoring of heart failure in the home setting.$331,659
Federal contractDepartment of Health and Human Services · SBIR Topic 97 - Phase II - Early Detection And Monitoring Of Cardiac Injury Due To Cardiotoxicity$724,602
Federal grantDepartment of Health and Human Services · Phase I · A Rapid Non-Invasive Device for Monitoring Preeclampsia in High Risk Pregnancy$215,450
Federal grantDepartment of Health and Human Services · Phase I · A rapid blood test to aid the triage of patients affected by head injuries.$223,966
Federal grantDepartment of Health and Human Services · Phase II · A COVID-19 Point of Care Serological Assay for Rapid Quantification of Antibody Titer.$240,405
Federal grantDepartment of Health and Human Services · Phase II · A COVID-19 Point of Care Serological Assay for Rapid Quantification of Antibody Titer.$1,060,897
Federal grantDepartment of Health and Human Services · Phase II · A COVID-19 Point of Care Serological Assay for Rapid Quantification of Antibody Titer.$97,316
Federal grantDepartment of Health and Human Services · Phase II · A COVID-19 Point of Care Serological Assay for Rapid Quantification of Antibody Titer.$398,753
Federal grant · SBIR/STTRFederal contract · USAspending

Peer position

Medtech · 4531 companies · ranked on federal contract value
Medtech companies ranked by federal contract value
#CompanyContractsDisclosed equity
325Xoran Technologies LLC$957K—
326Flashback Technologies, Inc.$950K$8.0M
327Neuroptics, Inc.$945K$2.3M
328ACCEL DIAGNOSTICS, LLC$937K—
329AUTONOMOUS HEALTHCARE INC.$925K—
330VITRUVIAN BIO, LLC$900K—
331COVARIS, INC.$900K—

Ranked on federal contract value rather than capital raised. The equity column is the comparison worth making — companies at the same procurement position often sit at very different points in their funding history.

Regulatory activity · Medtech

Sector-level, not company-level

Rules are matched to sector, not to company. Recent activity in a sector is context rather than a signal about this business — until rules are matched to what a company actually builds, the section is shown as context and nothing more.